Promising Platform for Cancer Immunotherapy
Celldex has flipped Dendreon's biological model on its head. With a goal of specifically and efficiently targeting a subset of immune cells in vivo, Celldex designed antibodies that bind to the internalization receptor (the DEC-205 receptor) on APCs, and are also tethered to the cancer antigen. The APC internalizes the antibody/antigen complex, and can then signal to T-cells to begin the assault on cancerous tissue. This method has the benefits of classical vaccines, as well as the specificity and efficiency of Dendreon's Provenge, with a fraction of the cost.
A Promising Platform for Cancer Immunotherapy - BMY, CLDX, DNDN, MRK - Foolish Blogging Network
Posted by Editor BioBOOM, Inc.
- ▼ 2013 (23)
- ► 2008 (24)
- ► 2007 (65)
- ► 2006 (77)